Drug intelligence / Profile preview

IVL3025

Development stage: Preclinical
Lead developer: Inventage Lab
Modality: Small Molecules
Administration: Subcutaneous

Overview

IVL3025 is a preclinical-stage long-acting injectable (LAI) small molecule GLP-1 receptor agonist being developed by Inventage Lab. It is designed for the treatment of metabolic disorders, specifically type 2 diabetes and obesity. The drug utilizes Inventage Lab's proprietary microsphere-based drug delivery technology, IVL-DrugPol™, which enables the sustained release of the small molecule therapeutic over an extended period. This formulation aims to improve patient compliance and provide a more stable pharmacokinetic profile compared to daily oral small molecule GLP-1 agonists or frequent peptide-based injections.

Targets

GLP1R (GLP-1R)

Beyond the preview

Go deeper on IVL3025.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IVL3025.

Explore the full profile